Impact of local and systemic alendronate on simvastatin-induced new bone around periodontal defects

Journal of Periodontology

Volumn 83, Issue 12, 2012, Pages 1463-1471

  Killeen, Amy C ^a   Rakes, Pota A ^a   Schmid, Marian J ^a   Zhang, Yijia ^b   Narayana, Nagamani ^a   Marx, David B ^c   Payne, Jeffrey B ^a   Wang, Dong ^b   Reinhardt, Richard A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Alendronate; Bone regeneration; Drug delivery systems; Histology; Simvastatin; Wound healing

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; BONE REGENERATION; DRUG EFFECT; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MANDIBLE; RAT; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ALENDRONATE; ALVEOLAR BONE LOSS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; MANDIBLE; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 84871064499     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2012.110683     Document Type: Article

References (43)

1. Bashutski JD, Wang HL. Biologic agents to promote periodontal regeneration and bone augmentation. Clin Adv Periodontol 2011;1:80-87.
2. Rosling B, Nyman S, Lindhe J. The effect of systematic plaque control on bone regeneration in infrabony pockets. J Clin Periodontol 1976;3:38-53.
3. Garrett S. Periodontal regeneration around natural teeth. Ann Periodontol 1996;1:621-666.
4. Gurgel BC, Ribeiro FV, Silva MA, et al. Selective COX-2 inhibitor reduces bone healing in bone defects. Braz Oral Res 2005;19:312-316.
5. Stein D, Lee Y, Schmid MJ, et al. Local simvastatin effects on mandibular bone growth and inflammation. J Periodontol 2005;76:1861-1870.
6. Sculean A, Pietruska M, Schwarz F, Willershausen B, Arweiler NB, Auschill TM. Healing of human intrabony defects following regenerative periodontal therapy with an enamelmatrix protein derivative alone or combined with a bioactive glass. A controlled clinical study. J Clin Periodontol 2005;32:111-117.
7. Tu YK, Woolston A, Faggion CM Jr. Do bone grafts or barrier membranes provide additional treatment effects for infrabony lesions treated with enamel matrix derivatives? A network meta-analysis of randomized-controlled trials. J Clin Periodontol 2010;37:59-79.
8. Yassibag-Berkman Z, Tuncer O, Subasioglu T, Kantarci A. Combined use of platelet-rich plasma and bone grafting with or without guided tissue regeneration in the treatment of anterior interproximal defects. J Periodontol 2007;78:801-809.
9. Jayakumar A, Rajababu P, Rohini S, et al. Multicentre, randomized clinical trial on the efficacy and safety of recombinant human platelet-derived growth factor with b-tricalcium phosphate in human intraosseous periodontal defects. J Clin Periodontol 2011;38:163-172.
10. Trombelli L, Farina R. Clinical outcomes with bioactive agents alone or in combination with grafting or guided tissue regeneration. J Clin Periodontol 2008;35(Suppl. 8):117-135.
11. Sculean A, Windisch P, Szendröi-Kiss D, et al. Clinical and histologic evaluation of an enamel matrix derivative combined with a biphasic calcium phosphate for the treatment of human intrabony periodontal defects. J Periodontol 2008;79:1991-1999.
12. Schwarz F, Rothamel D, Herten M, Ferrari D, Sager M, Becker J. Lateral ridge augmentation using particulated or block bone substitutes biocoated with rhGDF-5 and rhBMP-2: An immunohistochemical study in dogs. Clin Oral Implants Res 2008;19:642-652.
13. Jung RE, Glauser R, Schärer P, Hämmerle CH, Sailer HF, Weber FE. Effect of rhBMP-2 on guided bone regeneration in humans. Clin Oral Implants Res 2003;14:556-568.
14. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949.
15. Lee Y, Schmid MJ, Marx DB, et al. The effect of local simvastatin delivery strategies on mandibular bone formation in vivo. Biomaterials 2008;29:1940-1949.
16. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-1678.
17. Yaffe A, Binderman I, Breuer E, Pinto T, Golomb G. Disposition of alendronate following local delivery in a rat jaw. J Periodontol 1999;70:893-895.
18. Yaffe A, Kollerman R, Bahar H, Binderman I. The influence of alendronate on bone formation and resorption in a rat ectopic bone development model. J Periodontol 2003;74:44-50.
19. Meraw SJ, Reeve CM, Wollan PC. Use of alendronate in peri-implant defect regeneration. J Periodontol 1999;70:151-158.
20. Pradeep AR, Thorat MS. Clinical effect of subgingivally delivered simvastatin in the treatment of patients with chronic periodontitis: A randomized clinical trial. J Periodontol 2010;81:214-222.
21. Veena HR, Prasad D. Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects. J Indian Soc Periodontol 2010;14:40-45.
22. Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: A randomized, controlled clinical trial. J Periodontol 2012;83: 11-18.
23. Sharma A, Pradeep AR. Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: A randomized controlled clinical trial. J Periodontol 2012;83:19-26.
24. Lee Y, Liu X, Nawshad A, Marx DB, Wang D, Reinhardt RA. Role of prostaglandin pathway and alendronatebased carriers to enhance statin-induced bone. Mol Pharm 2011;8:1035-1042.
25. Jadhav SB, Jain GK. Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol 2006;58:3-18.
26. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003;1:45-52.
27. Kaynak D, Meffert R, Bostanci H, Günhan O, Ozkaya OG. A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the ratmandible. J Periodontol 2003;74:1348-1354.
28. Menezes AM, Rocha FA, Chaves HV, Carvalho CB, Ribeiro RA, Brito GA. Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. J Periodontol 2005;76:1901-1909.
29. Rocha ML, Malacara JM, Sánchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: A randomized placebo-controlled trial. J Periodontol 2004;75:1579-1585.
30. Jeffcoat MK, Cizza G, Shih WJ, Genco R, Lombardi A. Efficacy of bisphosphonates for the control of alveolar bone loss in periodontitis. J Int Acad Periodontol 2007;9:70-76.
31. Lane N, Armitage GC, Loomer P, et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: Results of a 12-month, randomized, placebo-controlled study. J Periodontol 2005;76:1113-1122.
32. King GN, King N, Cruchley AT, Wozney JM, Hughes FJ. Recombinant human bone morphogenetic protein-2 promotes wound healing in rat periodontal fenestration defects. J Dent Res 1997;76:1460-1470.
33. Liu XM, Lee HT, Reinhardt RA, Marky LA, Wang D. Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity. J Control Release 2007;122:54-62.
34. Altundal H, Güvener O. The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg 2004;33:286-293.
35. Bradley JD, Cleverly DG, Burns AM, et al. Cyclooxygenase- 2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo. J Periodontal Res 2007;42:267-273.
36. Seto H, Ohba H, Tokunaga K, Hama H, Horibe M, Nagata T. Topical administration of simvastatin recovers alveolar bone loss in rats. J Periodontal Res 2008;43:261-267.
37. Rutledge JE, Schieber MD, Chamberlain JM, et al. Simvastatin application to augment facial jaw bone in a dog model: Pilot study. J Periodontol 2011;82:597-605.
38. Kostopoulos L, Karring T. Role of periosteum in the formation of jaw bone. An experiment in the rat. J Clin Periodontol 1995;22:247-254.
39. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: Potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73:813-822.
40. Liu XM, Wiswall AT, Rutledge JE, et al. Osteotropic beta-cyclodextrin for local bone regeneration. Biomaterials 2008;29:1686-1692.
41. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010;363:2396-2405.
42. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract 2012;12 (Suppl. 3):233-247.
43. Bedogni A, Bettini G, Totola A, Saia G, Nocini PF. Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: A case report and literature review. J Oral Maxillofac Surg 2010;68:1662-1666.